The European Society of Cardiology (ESC), which represents more than 100,000 health care professionals, today urges EU health ministers to prevent a shortfall of essential medical devices for cardiovascular patients.
The call comes ahead of the Employment, Social Policy, Health and Consumer Affairs Council (EPSCO) meeting on 9 December, when ministers will discuss ongoing challenges in implementing the Medical Device Regulation (MDR) and the resulting risk of safe medical devices being removed from the EU market. Insufficient availability would have dire consequences for the diagnosis and treatment of cardiovascular patients, especially vulnerable groups including children and those with rare diseases.
Concerns about the transition to the MDR led the ESC, together with the Biomedical Alliance in Europe, to conduct a survey asking clinicians if devices they use are no longer on the market. ESC responses were the large majority (41%), with 21 EU countries and different subspecialties represented, ranging from pediatric cardiology to arrhythmology and cardiac surgery.
Results from ESC respondents:
The devices reported as missing from the market included diagnostic and ablation catheters, some stents, and devices used in pediatrics. The reported causes for unavailability included manufacturers withdrawing products due to the length and cost of MDR recertification and, in parallel, disruptions of supply chain and delivery issues.
The ESC supports the MDR's aim to enhance patient safety by improving the standards of clinical evidence required for medical devices, and welcomes the measures suggested by the Medical Device Coordination Group (MDCG) to facilitate the transition to the MDR. However, the ESC believes that stronger action is needed to avert this added threat to public health while healthcare systems are still reeling from the COVID-19 pandemic.
The ESC invites the European Commission and Member States to consider extending the recertification deadline of 26 May 2024. During this additional period, notified bodies should be given extra capacity to process recertification applications, while manufacturers would have more time to adjust to the regulations and cope with supply chain problems. The ESC also asks regulators to explore the opportunity for joint procurement actions to counteract shortages.
In addition, the ESC encourages the adoption of specific regulatory provisions to support the development and certification of orphan devices and it supports the possibility of conditional approval pathways.
The ESC also highlights that scientific societies can play a key role in providing expertise and data on medical devices through running registries.
In parallel, the ESC believes that additional measures should be taken to support research and innovation in the medical device field in Europe to stop investments shifting to other markets, which would slow down innovation, affect independent research organizations and academia, and further limit patient access to novel medical devices.
As summarized by the Chairman of the ESC Regulatory Affairs Committee, Piotr Szymański, "solutions are urgently needed to mitigate the medical devices crisis, that threatens medical procedures, research and innovation in Europe."
Citation: European cardiologists call for urgent action to prevent medical device shortages (2022, December 7) retrieved 9 December 2022 from https://medicalxpress.com/news/2022-12-european-cardiologists-urgent-action-medical.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
A cardiologist who holds medical privileges at Cape Cod Hospital is suing the hospital, saying he was defamed and fired from his full-time position after raising concerns about ethics and safety in cardiac care.
Dr. Richard Zelman, who was medical director of the hospital’s Heart and Vascular Institute, filed the lawsuit Tuesday in Barnstable Superior Court against Cape Cod Hospital, parent company Cape Cod Healthcare, and CEO Mike Lauf.
He said they “placed profit above all else” in ways that, in his view, compromised patient safety.
Zelman alleges that Lauf prohibited the use of a particular medical device on patients whose insurance plans reimbursed at a lower rate than others. The device, called Sentinel, is designed to reduce stroke risk during heart-valve replacement.
The insurance plans were managed-care plans, such as Medicare Advantage and Medicaid managed care, he said.
In addition, Zelman contends that he reported incidents of “dangerous care” by two cardiac surgeons, and that patients died in those cases.
He said the hospital failed to take action to protect patients and retaliated against him and other whistleblowers.
Zelman is an interventional cardiologist, meaning he does catheter-based treatments — such as angioplasty and placement of stents — but not surgery.
Cape Cod Healthcare denies all of the allegations.
In a written statement, the company said it particularly denies any claims of retaliation against Zelman and denies failing to take action, “when appropriate, to continue to Excellerate the quality of the Hospital’s cardiac care and services.”
The hospital said it values its physicians, nurses, and other staff who care for cardiology patients.
“The allegations are a disservice to the hard work of these professionals,” it said.
The hospital said it will defend the case vigorously.
A former Cape Cod Hospital cardiologist says he was dismissed and defamed after raising concerns about botched surgeries and poor ethical practices at the hospital.
In a lawsuit filed in Barnstable Superior Court on Tuesday against the hospital and its CEO, Dr. Richard Zelman alleged that the hospital prioritized profits over patient safety and public health.
According to the lawsuit, Cape Cod Hospital CEO Michael Lauf tried to limit the use of a medical device to patients whose insurance reimbursed at higher rates. Additionally, Zelman said Lauf and others retaliated against him after he reported what he saw as “grievously dangerous care” by the hospital’s cardiac surgeons, who were employed by Brigham and Women’s Hospital.
In a statement, Cape Cod Hospital noted that Zelman was no longer employed there and denied the claims Zelman made in the complaint, in particular that the physician had experienced retaliation for raising patient safety issues and that the hospital didn’t take action to Excellerate cardiac care at the facility.
“Indeed, our patient safety record is stellar and has never been compromised for any reason,” a hospital spokesman said in a statement. “We will not allow the good work of our dedicated physicians, nurses and other valued staff members to be undermined by specious allegations spurred on by an individual with personal objectives whose goal had been to gain leverage in employment contract negotiations. This tactic failed and we look forward to sharing the complete story, including Dr. Zelman’s own role in it.”
The hospital noted that Zelman has retained full medical staff privileges at the hospital and has continued to perform cardiac procedures there. However, a panel of hospital medical staff held a hearing on Wednesday that could lead to those privileges being revoked, Zelman said through a representative.
Zelman is seeking an undisclosed amount in damages, including for back pay, lost benefits, physical harm, and emotional distress.
An interventional cardiologist, Zelman began working at Cape Cod Hospital in 1990 while in private practice and accepted full-time employment there in 2006. He also contributed to the system’s founding of a Heart and Vascular Institute, becoming its medical director in 2018.
According to hospital tax documents, Zelman was the health system’s highest earner in 2020, the most latest year for which data is available. He out-earned the CEO with a $1.78 million total compensation package.Hospitals furloughed and laid off hundreds. Some executives still saw pay increases.
However problems started in 2019, when Zelman claims Lauf, the hospital’s CEO, limited the use of a device designed to filter out stroke-causing debris during certain procedures to patients whose insurance reimbursed at higher rates.
Zelman alleges that he raised the concerns not only with Lauf but with a previous chairman of the hospital’s Board of Trustees, who raised it with the current chair. Though the hospital subsequently changed its ways and allowed the devices to be used in all high-risk patients, hospital executives allegedly retaliated against Zelman, including investigating his performance, and stripping him of oversight duties.
According to the complaint, Zelman raised concerns again in 2021, reporting to Lauf and other hospital officials about what Zelman believed were several preventable patient deaths following procedures performed by the hospital’s two cardiac surgeons. All the patients, according to Zelman, were at low risk for complications.
Zelman also alleged that cardiac surgeons left the hospital during scheduled procedures, when they were expected to be on the premises.
In response, Lauf allegedly agreed that the cardiac surgeons’ mortality rate was “unacceptable,” but told Zelman that the supervision of cardiac surgeons was the responsibility of Brigham and Women’s Hospital, which employed the physicians, rather than Cape Cod Hospital, where the surgeons worked under a contractual agreement with the Brigham.
In a statement, Brigham and Women’s Hospital said they were still reviewing the complaint, and that “patient safety is our first priority and we regularly review our care to ensure it meets the highest quality standards.”
Both surgeons continued to work at the hospital, which Zelman alleged was because their procedures brought in a lot of revenue. One surgeon was ultimately removed from the hospital after he brought an automatic rifle to work.Cape Cod Hospital removes doctor who brought unloaded rifle to work
In October 2021, Zelman elevated his concerns to Dr. Raphael Bueno, the chief of thoracic and cardiac surgery at Brigham and Women’s Hospital. Bueno, according to the lawsuit, promised to send experienced surgeons to oversee the cardiac surgeons. But less than two weeks later, Zelman reported to Bueno that “catastrophic surgical outcomes” had occurred despite active supervision by the Brigham’s attending staff.
The surgical team at Cape Cod has since changed, and the hospital has switched its affiliation from the Brigham to Beth Israel Lahey Health.
Tensions escalated when the Brigham self-reported to the Centers for Medicare & Medicaid Services potential problems with how its Cape cardiac surgeons had documented valve replacement procedures. According to the lawsuit, an attorney for Cape Cod Hospital told Zelman the self-report was triggered by the Brigham’s fears that Zelman “‘would become a whistleblower,’ or words to that effect.” Ultimately, Brigham and Women’s issued a refund to CMS for all revenue it had derived from the procedures performed at Cape Cod over the prior six years. Cape Cod feared CMS would ask it, too, for a refund, putting millions of dollars in reimbursements at risk. It was unclear if Cape Cod ever refunded the revenue.
By January, Zelman claims in the complaint that Cape Cod Hospital leadership repudiated an agreed-upon contract extension. Though Zelman said he was not responsible for the way the procedures were billed, hospital leadership cited the billing concerns in its decision.
Lauf additionally launched an investigation into Zelman about allegedly deficient clinical patient care. The investigation then pivoted to focus on alleged regulatory and compliance concerns. By June the investigation was completed, but the report was never given to Zelman, according to the lawsuit.
Zelman said the hospital offered to let him keep his job, provided he issue a written statement that endorsed the quality and safety of all the hospital’s cardiac related programs, and specifically the cardiac surgery program. Zelman refused and, according to the suit, was ultimately terminated from the hospital at the end of September.
Cardiological Society of India, West Bengal Chapter, recently organised a three-day medical conference on advancement in medical science for controlling cardiovascular complications.
The conference was attended by Arindam Pande, organising secretary; Kashinath Ghosh Hazra, chairman Scientific Committee; Anjanlal Dutta, president CSI-WB branch; and around 500 doctors from all over West Bengal to exchange views on latest medical technologies.
The medical conclave with speakers of international and national repute had discussed the latest developments in the field of cardiology. “We, the West Bengal branch of Cardiological Society of India, always focus on heart ailments and to prevent and resolve them. We are here to exchange our vision and expertise on the advancement of medical science like new-age drugs and latest therapeutic aspects for the medical fraternities at large and also for the awareness of the communities in general,” said Ghosh Hazra.
The conference was organised keeping in view the leading cause of death in India is ischaemic heart disease or heart attack. Heart attack and heart failure are two health hazards that can seriously affect our lives if left untreated. Recognising the signs and symptoms of a heart attack can prevent many complications. Proper action against cardio-vascular risk factors like hypertension, diabetes can prevent the majority of heart disease.
The highlight of the conclave was not only the latest treatment procedure or new age medicines and its use in the management of cardiovascular issues but also the preventive cardiology to therapeutic interventions. Newer technology such as transcatheter aortic valve replacement along with new-era medicines in the management of heart failure, dyslipidemia, hypertrophic cardiomyopathy, anticoagulation was explained.
While talking about modern medicines, Arindam Pande, organising secretary, said “New-age medicines like SGLT 2 inhibitors reduce 38% chances of diabetes related macro-vascular complications like heart attack and stroke” on the eve of World Diabetes Day.
“The ailment in the aortic valve functioning is also a rising concern nowadays. There was a time when this problem could only be solved by open heart surgery. But now, through an interventional procedure, it is possible to replace this valve without surgery. This is called Trans-Catheter Aortic Valve replacement. The patients with aortic valve diseases may have shortness of breath, tightness in the chest, dizziness, swelling of the feet. Some of them might have signs like sudden fainting or loss of appetite as well,” added Pande.
Houston-based Texas Heart Medical Group is changing its name to the Texas Heart Institute Center for Cardiovascular Care as part of its move to a new location.
The rebrand reflects the heart center's new mission to focus on preventive cardiology, according to a Dec. 7 Texas Heart Institute news release. The Texas Heart Institute's new location is open and seeing patients, with a formal ribbon-cutting expected to take place in early 2023.
"We remain steadfast in our mission to Excellerate cardiovascular health through trailblazing research, thought leadership, education, and patient care. With an emphasis on quality, a spirit of inquiry and discovery, and a willingness to take bold action, today we have further our vision to deliver the future of cardiovascular care with the opening of our newly renovated center and announcement of our new name," Texas Heart Institute President and CEO Joseph Rogers, MD, said.
Scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) have identified a new therapeutic target for the prevention of heart failure linked to aortic stenosis. The study was led by Dr. Borja Ibáñez, Clinical Research Director at the CNIC, cardiologist at Hospital Universitario Fundación Jiménez Díaz, and member of the Spanish cardiovascular research network (CiberCV).
The study shows that overexpression in cardiac muscle cells of beta-3 adrenergic receptor, a member of the beta adrenergic system, can prevent or even reverse heart failure in a mouse model of aortic stenosis, a condition that currently has few therapeutic options.
In the study, published in Basic Research in Cardiology, the CNIC team adopted an innovative gene-therapy approach to boost the expression of this receptor in the heart and thus reinforce its beneficial action.
"Gene therapy has an enormous potential for the treatment of cardiac diseases. The next step will be to investigate this approach in animals with a heart more similar to that of humans, such as pigs, and then design a pilot clinical trial to translate these promising results to patients," explained study co-author and CNIC General Director Dr. Valentín Fuster.
Aortic stenosis is a progressive narrowing of the aortic valve, a "floodgate" through which blood flows from the heart to the rest of the body. The progressive obstruction of the aortic valve impedes the supply of blood to the body organs and causes pressure to build within the heart. The extra force required to expel blood with each heartbeat generates a physical stress that deteriorates the heart muscle. The condition is currently treated by replacing the damaged valve with a prosthesis.
While valve replacement technology has become much less invasive and successfully recovers valve function, Dr. Ibáñez explained that the cardiac muscle, after years of being subject to stress, does not recover. Unfortunately, there is a lack of treatments able to Excellerate cardiac muscle function and thereby alleviate heart failure resulting from a long history of aortic stenosis.
In addition to the CNIC team led by Dr. Ibáñez's team, the study had input from groups based in Italy and the U.S.. The study exploited the beneficial properties of stimulating the beta-3 adrenergic receptor, which is abundant in adipose tissue and the bladder but weakly expressed in the heart. Previous research had shown that stimulation of this receptor, despite its low expression in the heart, has potentially beneficial effects on cardiac diseases.
Using rat heart muscle cells (cardiomyocytes) grown in culture, the researchers found that forced expression of beta-3 adrenergic receptor inhibited the hypertrophic growth of these cells when they were exposed to a hormonal stimulus.
Through a collaboration with the CNIC Intercellular Signaling in Cardiovascular Development and Disease group, led by Dr. Jose Luis de la Pompa, transgenic mice were generated that overexpress the beta-3 adrenergic receptor in cardiomyocytes.
"When these mice were subjected to supravalvular aortic stenosis, they developed less cardiac hypertrophy and fibrosis than mice with normal levels of expression. The transgenic mice were also free of heart failure, and their hearts were metabolically more efficient and consumed less glucose," explained Dr. Andrés Pun, first author on the study.
These results prompted the scientists to study the cardiomyocytes' mitochondria, the energy production hubs in cells. "Because heart muscle has such high energy requirements, any damage to its mitochondria can have catastrophic consequences, as frequently occurs in heart failure," said Dr. Pun.
In healthy hearts, mitochondria mainly burn fatty acids, which provide a highly efficient generation of abundant amounts of energy. Nevertheless, said Dr. Pun, "the failing heart often switches to the use of glucose, a much less efficient energy source, and this contributes to the progression of the disease."
In addition, the mitochondria of the failing heart are unable to fuse efficiently and are therefore smaller and more prone to accumulating injuries. The investigators found that the cardiomyocyte mitochondria in the transgenic mice were much larger and healthier.
Since the transgenic technology used to develop these mice is not applicable in patients, the investigators developed a gene therapy approach, whereby an innocuous virus was injected into mice to deliver the beta-3 adrenergic receptor gene specifically to cardiomyocytes, resulting in safe and efficient production of the receptor.
Working in partnership with the CNIC Viral Vectors Unit, the team designed an innocuous virus able to enter cardiomyocytes and drive elevated expression of beta-3 adrenergic receptor in the hearts of non-transgenic adult mice. When these mice were subjected to aortic stenosis, they were as equally protected against heart failure as transgenic mice overexpressing the receptor from before birth.
In a final test, the team injected the virus into non-transgenic mice with long-lasting aortic stenosis and established heart failure. In these mice, gene-therapy–induced overexpression of beta-3 adrenergic receptor recovered heart function, reduced cardiomyocyte hypertrophy, restored normal mitochondrial size and normal expression of mitochondrial fusion proteins in the heart, and increased animal survival.
Provided by Centro Nacional de Investigaciones Cardiovasculares Carlos III (F.S.P.)
Citation: A new therapeutic target for the prevention of heart failure due to aortic stenosis (2022, November 30) retrieved 9 December 2022 from https://medicalxpress.com/news/2022-11-therapeutic-heart-failure-due-aortic.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
Nearly 1 in 3 deaths worldwide is related to heart disease, the World Health Organization reports. While some of our overall risk is impacted by uncontrollable factors, such as age and genetics, many forms of heart disease are drastically impacted by our daily habits. (Psst ... the Centers for Disease Control and Prevention has more about the action steps you can take to try to prevent heart disease.)
Pictured Recipe: Mixed Vegetable Salad with Lime Dressing
Sleep enough, stress less, move some; there are certain strategies nearly all health experts can agree upon related to supporting heart health. But there's an ongoing conversation around what eating style is best to help you take heart.
Shifting from the standard American diet to one that's richer in fruits and vegetables may lower relative heart disease risk by 9.9%, and following a DASH diet might reduce risk by 10.3%, according to a study set to be published January 15, 2023, in The American Journal of Cardiology.
Ahead, a closer look at how the researchers landed at this conclusion, a primer for how to follow the DASH diet, and a week's-worth of heart-healthy dinner ideas to add to your meal plan this week.
Related: 5 Surprising Heart-Healthy Foods You Should Be Eating
Scientists from the Beth Israel Deaconess Medical Center at Harvard Medical School recruited 437 participants, with an average age of 45, and asked them to follow what they deemed the "typical American diet" for three weeks to kick things off. This included little fresh produce and was fairly high in total fat, saturated fat and cholesterol.
After that three-week foundation, they randomly assigned each person to one of three groups, which followed a specific eating style for the next eight weeks:
The three groups were fairly consistent in terms of body size, hypertension status and physical exercise levels.
After the two-month diet trial, the researchers estimated the participants' atherosclerotic cardiovascular disease risk using a predictive mathematical process called the Pooled Cohort Equation. This takes into account age, sex, race, blood pressure, cholesterol and other biometrics to calculate approximate heart disease risk over time.
Compared to the control "American" menu, those who ate a DASH-style menu appeared to have 10.3% lower relative risk for heart disease, while those who consumed the fruit- and vegetable-packed plan reduced risk by 9.9%. The absolute differences in risk—or the likelihood someone from this group would actually experience a cardiovascular event—were small, though, to the tune of 0.15%. That means that if 1,000 people shift from the higher-fat, lower-produce diet to a DASH plan, about two fewer people would be diagnosed with heart disease. The relative risk that the study measured compares the risk of heart disease for those following a standard American diet to the other dietary interventions.
Kick off the day with any of these 16 DASH diet breakfast recipes, follow that up with one of our 15 best DASH diet lunches, then keep the ticker-friendly treats going with our picks for your first week of DASH diet dinners. Designed with winter in mind, each of these is rich in vegetables, many showcase whole grains and plant-based protein (to help keep saturated fat levels in check), and all deliver a lot of cozy per calorie.
Related: Heart-Healthy Diet Plan for Beginners
Following a DASH diet, or any meal plan that's rich in fruits and vegetables, may help lower risk for heart disease, one new preliminary study says. This study was fairly small and short-term—it's really tough for eight weeks of trial time to completely predict heart disease risk 10 years in the future—so longer, more diverse and more controlled research is needed to confirm these results.
That said, this is one of many pieces of evidence that suggests that following a DASH-diet-style strategy can be a boon for your cardiovascular system. In fact, the DASH diet is ranked near the top on the list of best diets for heart health, according to the latest U.S. News & World Report rankings. And these findings support a continued focus on increasing access to enough fruits and vegetables for all individuals of all income levels and hometowns, the scientists confirm.
As we continue to learn more about the connection between eating more plants and less animal fat and a healthier heart, stock up on these heart-healthy foods during your next supermarket run. It's important to remember that there are other lifestyle factors involved in your overall heart disease risk profile, too. Stress, sleep, alcohol consumption, activity levels and more can impact your chances of having a heart attack, stroke or other form of cardiovascular disease, so be sure to consult with your medical care team to keep tabs on all of the above.
Up Next: This Simple Test Might Help Identify Your Risk for Heart Disease, According to Science
Read the original article on EatingWell
A new Israeli app can sound the alarm before the onset of congestive heart failure — just by analyzing the sound of a user’s voice.
A study with recovered patients found that the app predicted some 82 percent of relapses before they happened.
HearO “listens” to voice samples that users record on their smartphones and alerts them if they are at imminent risk of congestive heart failure. It works by detecting irregularities in an individual’s speech, comparing them to their healthy “baseline” voice. If anomalies are detected, doctors are immediately informed so they can take preventative action.
The new study was conducted by the company behind the app, Cordio Medical, in partnership with Beilinson Hospital, Barzilai Medical Center and Galilee Medical Center, as well as Clalit Health Services Cardiovascular Centers. It is currently undergoing peer review.
Patients who had experienced heart failure and were therefore deemed to have significant chances of a relapse used the HearO app at home and sent voice samples in Hebrew, Arabic or Russian. The 180 patients recorded several clips a day over two years, meaning there were 460,000 clips reviewed for the study.
Heart failure happens when the heart muscle’s ability to contract has been harmed over time or when it has a mechanical problem that limits its ability to fill with blood. The heart then can’t meet the body’s need for blood, and blood returns to the heart at a faster rate than it is pumped out. The heart becomes congested; hence the term congestive heart failure.
Cordio Medical CEO Tamir Tal said that around one-third of the patients experienced heart failure during the two-year study, as anticipated. When their medical records were cross referenced to the app’s analysis of their voice, it emerged that the app had predicted the failure in 82% of cases. It detected the warning signs roughly 18 days before an incident on average.
The study design, which was reviewed by ethics committees, meant that patients were not given the warnings in real time, but Tal said that when the app is launched, doctors would have a chance to change medication or provide extra care and could well avert many cases of heart failure relapse.
Tal said the study results indicate that the technology can save lives and “dramatically decrease the number of hospitalizations from congestive heart failure.”
The technology recently received approval from the Health Ministry and from the European Union. It is expected to receive FDA approval at the end of 2023. Tal said that the app is compliant with the US Health Insurance Portability and Accountability Act, which sets out standards for privacy, including requirements for patients to consent to all use of their data.
Users speak into their phone in a quiet room for around a minute several times a day, and the file is analyzed by artificial intelligence. “Just as when you call your mom and she immediately can tell from your voice if you’re not feeling well, the app uses AI to ‘read’ your voice and can tell when things are not as they should be,” Tal explained.
“Cardiologists have the ability to hear complications in their patients’ speech, but it’s normally too late, as the patients usually need to be hospitalized by this point. Nevertheless, our voice has a lot of data waiting to be mined. By constantly monitoring people and making use of this data, this platform can be a life-changing solution,” he added.
Israeli politics told straight
I joined The Times of Israel after many years covering US and Israeli politics for Hebrew news outlets.
I believe responsible coverage of Israeli politicians means presenting a 360 degree view of their words and deeds – not only conveying what occurs, but also what that means in the broader context of Israeli society and the region.
That’s hard to do because you can rarely take politicians at face value – you must go the extra mile to present full context and try to overcome your own biases.
I’m proud of our work that tells the story of Israeli politics straight and comprehensively. I believe Israel is stronger and more democratic when professional journalists do that tough job well.
Your support for our work by joining The Times of Israel Community helps ensure we can continue to do so.
Tal Schneider, Political Correspondent
You're a dedicated reader
We’re really pleased that you’ve read X Times of Israel articles in the past month.
That’s why we started the Times of Israel ten years ago - to provide discerning readers like you with must-read coverage of Israel and the Jewish world.
So now we have a request. Unlike other news outlets, we haven’t put up a paywall. But as the journalism we do is costly, we invite readers for whom The Times of Israel has become important to help support our work by joining The Times of Israel Community.
For as little as $6 a month you can help support our quality journalism while enjoying The Times of Israel AD-FREE, as well as accessing exclusive content available only to Times of Israel Community members.
David Horovitz, Founding Editor of The Times of Israel
The Center is moving to a new location designed to enhance patient care
HOUSTON, Dec. 7, 2022 /PRNewswire/ -- The Texas Heart Institute® announced today that the Texas Heart Medical Group has changed its name to The Texas Heart Institute Center for Cardiovascular Care. Over the past 6 decades, The Texas Heart Institute® has been internationally recognized for delivering exceptional clinical care in a sophisticated, patient-centered atmosphere. Today, the physicians and surgeons of The Texas Heart Institute Center for Cardiovascular Care are fully integrated with The Institute providing world-class care in addition to the latest and most innovative treatments for heart and vascular disease.
Aligned with the name change, the multidisciplinary cardiovascular center is moving to a newly renovated location on the 26th floor at 6624 Fannin Tower on December 7, 2022. The new office nearly doubles the existing clinic's footprint and is designed to enhance and personalize a patient-centric experience, while providing state-of-the-art technology.
"We remain steadfast in our mission to Excellerate cardiovascular health through trailblazing research, thought leadership, education, and patient care. With an emphasis on quality, a spirit of inquiry and discovery, and a willingness to take bold action, today we have further our vision to deliver the future of cardiovascular care with the opening of our newly renovated center and announcement of our new name," said Joseph G. Rogers, M.D., President, CEO of The Texas Heart Institute.
The name change signals a moment of recommitment from the renowned cardiac institution to move towards a future with an increased focus on preventive cardiology—and to ensure that The Texas Heart Institute Center for Cardiovascular Care remains a leader within the field.
The opening of The Texas Heart Institute Center for Cardiovascular Care brings together a level of expertise that attracts local, regional, and international patients. In our enhanced, state-of-the-art space, we'll continue to enroll patients in leading clinical research studies, as well as serve as a vital teaching location for our trainees and a resource for other cardiologists and cardiac surgeons seeking expert opinions for their most challenging cases," Eduardo Hernandez, M.D., President of The Texas Heart Institute Center for Cardiovascular Care.
The Texas Heart Institute Center for Cardiovascular Care will be open for patient appointments as of December 6th, with plans of a formal ribbon cutting for the space to commence in early 2023.
About The Texas Heart Institute Center for Cardiovascular Care
Since its inception in 1962, The Texas Heart Institute has provided exceptional care to patients from around the world. The Texas Heart Institute Center for Cardiovascular Care is its clinical practice specializing in cardiovascular care in a sophisticated, welcoming, patient-centric atmosphere. Fully integrated with The Texas Heart Institute's research and education arms, The Texas Heart Institute Center for Cardiovascular Care attracts local, regional, and international patients seeking excellent cardiovascular care as well as cardiologists and heart surgeons looking for expert opinions for their most challenging cases. Texasheartmedical.org
About The Texas Heart Institute®
The Texas Heart Institute is an independent, nonprofit organization that is improving cardiovascular health through trailblazing research, thought leadership, education, and patient care. Located within the Texas Medical Center in Houston, Texas, and founded in 1962 by renowned cardiac surgeon Dr. Denton Cooley, The Texas Heart Institute performed the first successful heart transplant and total artificial heart implant in the United States. Since then, our physicians and surgeons remain recognized as worldwide leaders in the diagnosis and treatment of even the most complex cardiovascular conditions. Research programs at The Texas Heart Institute continue to push the boundaries of cardiovascular science by translating laboratory discovery to patient care. The Texas Heart Institute has been ranked among the top cardiovascular centers in the United States by U.S. News & World Report for more than 30 years. www.texasheart.org
View original content to obtain multimedia:https://www.prnewswire.com/news-releases/texas-heart-medical-group-is-now-the-texas-heart-institute-center-for-cardiovascular-care-301696138.html
SOURCE The Texas Heart Institute